Urokinase, CX3CL1, CCL2, TRAIL and IL‐18 induced by interferon‐β treatment

Objective To identify serum proteins associated with MS and affected by interferon beta treatment. Methods Plasma samples from 29 untreated relapsing-remitting patients 15 healthy controls were investigated a multiplexed panel containing 92 related to inflammation. Follow-up available 13 at 1 3 months after initiation of treatment beta-1a. Results Ten differentially expressed in patients. Five these altered IFN-β 1a: uPA, CX3CL1, CCL2, TRAIL IL18. Conclusion CCL2 confirmed be modulated MS. As novel findings, we now report that uPA CX3CL1 increased IFN-beta-1a Conflicting results have been reported on how affects IL-18.